|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report - Crohn’s Disease, Ulcerative Colitis Q1 2010
Medpredict, March 2010, Pages: 120
In this last Gastroenterology Thought Leader Panel the publisher reported on key unmet needs in the treatment of Crohn’s disease and ulcerative colitis. In this report the publisher asks six internationally recognized experts in the treatment of inflammatory bowel disease to build on that, and engage with us in a thought exercise with the aim of ranking the most medically valuable initiatives in the developmental pipeline. Each thought leader was asked to identify the five agents that they were most looking forward to having available in the next few years - their “Fantasy Formulary.”
The Panel then turns to the more immediately commercially relevant question of comparing Simponi to other anti-TNF agents, next generation inhibitors of leukocyte trafficking to natalizumab and to each other, and both of these classes to p40 approaches.
The Panel was well represented by both very aggressive treaters, looking for stem cell transplants for everybody, and the very conservative treater who is looking to replace (whenever possible) biologicals and immunomodulators with more natural, homeopathic medicines. Each side makes their case.
Finally, Panelists comment on recent clinical setbacks for Humira in ulcerative colitis, and thoughts on Cimzia, 5-ASA products, new steroids, probiotics, oral small molecules (tasocitinib, apremilast, others) and newer biological approaches (e.g. IL-17, innate immunostimulators).
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
